American Academy of Dermatology selects AOBiome study for presentation at Annual Meeting

Latest News

American Academy of Dermatology selects AOBiome study for presentation at Annual Meeting

Improving the Appearance of Keratosis Pilaris with Ammonia Oxidizing Bacteria

Cambridge, MA, March 4, 2017
Presented at the Late-breaking Forums during the 2017 Annual Meeting in Orlando, FL, March 3-7, 2017 by:

Dr. Nicole Lee, MD, MPH

Saturday, March 4 from 10:50 AM - 11:00 AM

AUTHORS: Nicole Y Lee1, MD, MPH, Shilpi Khetarpal1, MD, Kathleen G Petrell1, Mariya Gaber2, Spiros Jamas2, ScD, Ioannis Gryllos2, PhD, D. Davidson Easson Jr2, ScD, Jeffrey S Dover1, MD, FRCPC

1 SkinCare Physicians, Chestnut Hill, MA
2AOBiome, LLC, Cambridge, MA


Keratosis pilaris is a common skin condition presenting as follicular hyperkeratotic papules on proximal extremities. The appearance is disturbing to patients and current therapies are limited. Nitric oxide (NO) is essential in systemic and cutaneous physiologic function, specifically its anti-microbial and anti-inflammatory properties, which evolutionarily may have been maintained by ammonia-oxidizing bacteria (AOB). We hypothesized that topical skin application of AOB (Nitrosomonas eutropha), a biological delivery system of nitrite and NO, could benefit KP patients. We evaluated tolerability and efficacy in a double-bind, placebo-controlled, bilateral study in subjects with KP on both arms and legs.

Read More.

Recent News
3 October 2017, Cambridge, MA
AOBiome Commences Patient Enrollment in Phase 1b/2a Clinical Trial of Ammonia Oxidizing Bacteria (AOB) for the Treatment of Seasonal Allergic Rhinitis

20 September 2017, Cambridge, MA
AOBiome Expands Intellectual Property Estate, Announces Issuance of U.S. Patent for Ammonia Oxidizing Bacteria (AOB) for the Treatment of Acne

13 April 2017, Cambridge, MA
AOBiome Completes Patient Enrollment In Phase 2 Clinical Trial Of Lead Candidate B244 To Treat Elevated Blood Pressure

4 March 2017, Cambridge, MA
American Academy of Dermatology selects AOBiome study for presentation at Annual Meeting

5 January 2017, Cambridge, MA
AOBiome Partners with iCarbonX and Secures $30 Million Investment for Drug Development

16 December 2016, Cambridge, MA
AOBiome Launches Phase 2 Clinical Trial Using Novel Bacterial Platform for Treatment of Hypertension

20 September 2016, Cambridge, MA
AOBiome Announces First-of-its Kind Trial of Live Topical Bacterial Treatment for Acne

31 December 2015, Cambridge, MA
AOBiome Wins Dermatology Entrepreneurship Shark Tank Contest

7 July 2015, Cambridge, MA
Mother Dirt Rethinks what it means to be Clean and Healthy with First-Ever Line of Biome-Friendly Products for the Skin

29 June 2015, Cambridge, MA
AOBiome co-founder, Jamie Heywood named by Scientific American, as one of The Worldview 100, The visionaries who continue to reshape biotechnology-and the world

22 June 2015, Cambridge, MA
AOBiome Announces Start of First Clinical Trial with Ammonia Oxidizing Bacteria-Based Therapeutic for Treatment of Acne

18 May 2015, Cambridge, MA
AOBiome Announces Three Senior Management Appointments

2 Oct 2014, Washington, DC
American Society for Microbiology Reports Sweat-Eating Bacteria May Improve Skin Health

20 Jun 2014, Cleveland, OH
Accelerated Healing of Diabetic Ulcer Data Presented

16 Jun 2014, Cambridge, MA
AOBiome in the News

19 May 2014, Cambridge, MA
AOBiome announces appointment of scientific advisory board

30 Jun 2013, Cambridge, MA
Nitrocell becomes AOBiome LLC